Dagmar Jürgens

QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers

Ewa A. Mirecka, A. Janssen, T. van Groen, 2015, Scientific Reports.

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology

T. van Groen, I. Kadish, D. Willbold, 2017, Scientific Reports.

Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study

M. Wolzt, M. Hümpel, D. Willbold, 2020, Alzheimer's & dementia.

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease

D. Willbold, B. Hutter-Paier, Markus Tusche, 2017, Molecules.

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology

T. van Groen, I. Kadish, D. Willbold, 2017, Scientific Reports.

Aβ oligomer eliminating compounds interfere successfully with pEAβ(3–42) induced motor neurodegenerative phenotype in transgenic mice

K. Langen, H. Demuth, D. Willbold, 2017, Neuropeptides.

Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease

M. Hümpel, D. Willbold, S. Halbgebauer, 2023, Heliyon.

An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain

A. Willuweit, Ian Gering, Dagmar Jürgens, 2023, British journal of pharmacology.